Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Síntesis de sistemas dendríticos de tamaño nanoscópico para aplicaciones en biomedicina


Oferta Tecnológica
Un grupo de investigación español especializado en compuestos organometálicos ha desarrollado una tecnología de síntesis y caracterización estructural de sistemas dendríticos de tamaño nanoscópico para el transporte y liberación de medicamentos como vehículo de transfección en terapia de genes o como agentes terapéuticos. El método consiste en la preparación de moléculas de tamaño nanoscópico basadas en sistemas dendríticos o polímeros hiper-ramificados que contienen un esqueleto carbosilano y que están funcionalizados en la periferia con grupos de distinta naturaleza (catiónicos, aniónicos o neutros), con el objetivo de dotarles de actividad para distintos fines biomédicos. Se buscan empresas de los sectores de química, farmacia y biotecnología con el fin de establecer acuerdos de cooperación en materia de investigación, joint venture y licencia.


Synthesis of dendritic systems of nanoscopic size for applications in biomedicine.
A Spanish research group on organometallics has developed a technology consisting in the synthesis and structural characterization of dendritic systems of nanoscopic size for the transport and release of drugs as a vehicle of transfection in gene therapy or as therapeutic agents. The group is looking for companies from the chemistry, pharmaceutical or biotechnology sector for collaboration in research cooperation, joint venture and licensing agreements.
In order to fight with viral diseases and those caused by bacteria, i.e. H.IV (Human Immunodeficiency Virus); Health sector, especially pharmaceutical companies, is looking to develop new drugs and new ways to drug delivery. This new drugs and delivery systems try to achieve a higher therapeutic effect in humans or animals.
Development of new drug molecule is expensive and time consuming. So, improving safety efficacy ratio of "old" drugs, by new delivery systems, is being attempted. These new methods are individualizing drug therapy, dose titration, delivering drug at controlled rate, slow delivery, targeted delivery among others.
A Spanish research group, at a public university working on organometallics, has developed a new technology for the transport and released of drugs. The method consisting on the preparation of molecules of nanoscopic size based on dendritic systems or hyperbranched polymers that contains a carbosilane skeleton and are functionalized in the periphery with groups from different nature (cationic, anionic or neutral), with the objective to provide them with activity focused in different biomedical aims. Among these applications, it can be emphasized the development of cationic dendrimers appropriate for the transport of anionic drugs or as non-viral vehicles in transfection processes in gene therapy, because of its capacity to join biomolecules with negative charge as oligonucleotides or siRNA (short interfering RNA). These cationic systems can also act as therapeutic antibacterial agents (against gram + bacterial and gram - bacterial) or as anti-prionic agents.
The group has proved that cationic dendritic systems of carbosilane type are able to join by an electrostatic interaction oligonucleotides or small RNA of interference (si RNA), making complexes that have proved not to be toxic in concentration among 1-5 micromolar. These complexes are able to internalise the genetic material inside different types of cellular lines and in some cases they have showed a great efficiency in the inhibition of HIV (Human Immunodeficiency Virus). They have also showed to be useful in processes of transfection of plasmids to different cellular carcinogenic lines in vitro and in vivo, being observed in some cases percentages of transfection bigger to those that are obtained by the use of commercial transfectants.
Regarding the antibacterial capacity of these cationic systems, the group has proved that they present a great activity against gram + bacteria and gram - bacteria, and in addition there are signs of strengthening of the antibacterial activity of penicillin when it joins one of the dendritic systems.
The technology developed allows also the preparation of anionic systems that present an important antiviral activity, mainly against HIV. That´s why, these system are proposed as good candidates for the development of a powerful microbicide for external use that avoids the infection for HIV by sexual transmission. Besides this microbicide capacity, these systems have showed antiinflammatory properties what reinforces his inhibitory capacity.

The functionalization with neutral groups, has been carried out incorporating oligosacharides into the periphery of the dendritic systems developed what awards to these systems antimicrobial properties.

All the synthesized macromolecules have been characterized using different techniques of structural elucidation as elementary analysis, spectroscopy of RMN (Nuclear Magnetic Resonance), IR (Infrared spectroscopy) or UV (Ultraviolet-visible spectroscopy), mass spectrometry or GPC (Gel permeation chromatography).

The group is looking to reach research cooperation agreements, joint venture agreements and licensing agreement. They are looking for companies from the chemistry, pharmaceutical or biotechnology sector.
Advantages and Innovations:

Regarding the cationic systems developed, the principal innovative aspects are the following:

-They are non viral nanoscopic synthetic molecules able to internalise nuclear material inside different cellular lines. This turns them into good candidates to be considered as non viral vectors in gene therapy processes.
-They are non toxic in a concentration range adapted for the accomplishment of different biomedical studies.
-They present antibacterial properties against gram + and gram- bacteria
-They are able of interacting, in a electrostatic way, with anionic drugs which turns them into drug delivery systems.
-They present a hydrophobic carbosilane skeleton that allows the molecules to cross the cellular membranes with major facility.
-They are soluble in water.

Regarding the anionic systems developed, the principal innovative aspects are the following:

-They have an important antiviral capacity
-They are able to inhibit the infection for HIV
-They have antiinflammatory capacity
-They are good candidates for the production of a microbicide gel of topic use that prevents the infection of the virus across sexual transmission.


Regarding the cationic systems developed, the principal competitive advantages are the following:

-Cheaper preparation than other commercial transfection agents.
-Minor toxicity than other commercial transfection agents..
-Levels of transfection similar or superior to commercial alternatives (depending on the cellular line used)
-Antibacterial capacity against to a wide spectrum of bacteria

Regarding the anionic systems developed, the principal competitive advantages are the following:

-They present a great antiviral capacity, mainly against HIV virus.
-They have antiinflammatory activity.
-They can be in use in the development of a microbicide gel of topic use.
Stage of Development:
Under development/lab tested
Patents granted
CommeR Statunts Regarding IPR Status:
National patent.

Partner sought

Type and Role of Partner Sought:
The research group is looking for joint venture agreements, but it is also open to achieve licensing or research cooperation agreements with companies from the chemistry, pharma or biotechnology sector.
The role of the partner will depend on the type of agreement and will be discuss with the company after first contact.


Type and Size of Client:
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
05001004 Química orgánica
06001009 Terapia genética - ADN